TY - JOUR
T1 - Comparative study on the usefulness of antibacterial prophylaxis with levofloxacin in patients submitted to hematopoietic stem cell transplantation
AU - Fernandez Sojo, Jesús
AU - Batlle Massana, Montserrat
AU - Morgades, Mireia
AU - Vives Polo, Susana
AU - Quesada, María Dolores
AU - Ribera Santasusana, Josep María
PY - 2016/1/1
Y1 - 2016/1/1
N2 - © 2015 Elsevier España, S.L.U. Background Bacterial infection remains a frequent complication in patients receiving a hematopoietic stem cell transplantation (HSCT). However, the impact of the antibacterial prophylaxis mortality in these patients is controversial. Patients and methods Retrospective comparison of 2 consecutive groups of patients undergoing HSCT receiving (n = 132) or not (n = 107) antibacterial prophylaxis with levofloxacin. Results 41% of patients receiving prophylaxis with levofloxacin had microbiologically documented infection (MDI) with bacteremia, compared with 40% of those not receiving levofloxacin. The frequency of gram-negative bacteremia was 11 and 38%, the resistance to levofloxacin was 39 and 14%, and the mortality was 8 and 7%, respectively. Conclusions In our experience, the use of levofloxacin as prophylaxis in HSCT was associated with a lower frequency of gram-negative bacteremia but was not associated with a decreased rate of MDI and did not influence their outcome. In contrast, there was an increase in quinolone resistance in patients treated with levofloxacin.
AB - © 2015 Elsevier España, S.L.U. Background Bacterial infection remains a frequent complication in patients receiving a hematopoietic stem cell transplantation (HSCT). However, the impact of the antibacterial prophylaxis mortality in these patients is controversial. Patients and methods Retrospective comparison of 2 consecutive groups of patients undergoing HSCT receiving (n = 132) or not (n = 107) antibacterial prophylaxis with levofloxacin. Results 41% of patients receiving prophylaxis with levofloxacin had microbiologically documented infection (MDI) with bacteremia, compared with 40% of those not receiving levofloxacin. The frequency of gram-negative bacteremia was 11 and 38%, the resistance to levofloxacin was 39 and 14%, and the mortality was 8 and 7%, respectively. Conclusions In our experience, the use of levofloxacin as prophylaxis in HSCT was associated with a lower frequency of gram-negative bacteremia but was not associated with a decreased rate of MDI and did not influence their outcome. In contrast, there was an increase in quinolone resistance in patients treated with levofloxacin.
KW - Bacteremia
KW - Hematopoietic stem cell transplant
KW - Levofloxacin
KW - Prophylaxis
KW - Resistance
UR - https://www.scopus.com/pages/publications/84955652786
U2 - 10.1016/j.medcli.2015.05.019
DO - 10.1016/j.medcli.2015.05.019
M3 - Article
SN - 0025-7753
VL - 146
SP - 16
EP - 19
JO - Medicina Clinica
JF - Medicina Clinica
IS - 1
ER -